Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022.

"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: ARK declares stock and other ownership interests: ECOM Medical. Consulting or advisory role: Exelixis, AstraZeneca, Bayer, Pfizer, Novartis, Genentech, Bristol Myers Squibb, EMD Serono, Immunomedics, and Gilead Sciences. Speakers’ bureau: Janssen, Astellas Medivation, Pfizer, Novartis, Sanofi, Genentech/Roche, Eisai, AstraZeneca, Bristol Myers Squibb, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/Astellas, Myovant Sciences, Gilead Sciences, and AVEO. Research funding: Genentech, Exelixis, Janssen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, MacroGenics, Astellas Pharma, BeyondSpring Pharmaceuticals, BioClin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics, and Epizyme. Travel, accommodations, and expenses: Genentech, Prometheus, Astellas Medivation, Janssen, Eisai, Bayer, Pfizer, Novartis, Exelixis, and AstraZeneca. David Joseph Benjamin has the following disclosures: Consulting: Seagen. Speakers’ bureau: Merck. Travel and accommodations: Merck."

"Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article."